Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imatinib Teva

- PMLiVE

Novartis begins sale talks for Horsham, UK site

Enters negotiations with the University of Brighton

- PMLiVE

Novartis launches another localised NHS eye service in UK

Will provide specialised care to people of Coventry

- PMLiVE

Teva’s generic Nexium wins US approval

FDA backs copy of AstraZeneca’s heartburn drug

- PMLiVE

Abraxane on course for lung cancer indication in EU

CHMP backs news indication for Celgene drug

EU flag

Antibiotics among 7 new drugs backed by EMA

The Medicines Company’s Orbactiv and Cubist’s Sivextro set for European approval

- PMLiVE

CHMP thumbs up for Novo’s obesity drug Saxenda

Diabetes drug liraglutide on course for new indication in EU

- PMLiVE

Novartis’ Cosentyx cleared for psoriasis in Europe

First of the IL-17 inhibitor classof drug to receive European approval

- PMLiVE

Novartis forms digital health investment company with Qualcomm

Expands work with Tricorder prize firm to develop 'beyond-the-pill' initiatives

Novartis building

Novartis files COPD combo in US

QVA149 combines long-acting beta agonist with long-acting muscarinic antagonist

- PMLiVE

Novartis completes sale of animal health unit to Lilly

$5.4bn deal is finalised

- PMLiVE

Novartis signs stem cell research pact with Intellia

Will work with the biotech start-up on creating new treatments

Novartis day

FDA close to first biosimilar approval

US regulator’s advisory board recommends Novartis’ version of Amgen’s Neupogen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links